DR3 (CT) Blocking Peptide
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Product Concentration 0.2 mg/ml Amino Acid Location This peptide sequence is located at amino acids 398 to 417 of Human DR3 protein. Formulation This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide. Storage and Handling Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day Ambient Amino Acid Sequence 20 amino acids near the carboxy terminus of human DR3. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionBackground DR3 peptide is applicable as a control peptide for blocking antibody binding in Western blotting. References & Citations1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682
2. Pitti RM; Marsters SA; Ruppert S; Donahue CJ; Moore A; Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996;271:12687-90
3. Pan G; O'Rourke K; Chinnaiyan AM; O'Rourke K; Gentz R; Ebner R; Ni J; Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science; 1997;276:111-113
4. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997;7:831-836 |
Related Products
- -
- -
Prod No. | Description |
---|---|
D252 | |
D253 | |
D283 | |
D274 | |
D276 | |
D344 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.